title: Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke.
abstract: BACKGROUND
  Despite current preventive therapies, patients with transient ischemic attack (TIA) and ischemic stroke remain at high risk for recurrent brain disease and cardiovascular events. In an effort to develop new therapies, abnormal glucose tolerance has recently been proposed as an interventional target. Among persons not otherwise known to be diabetic, impaired glucose tolerance (IGT) and diabetic glucose tolerance (DGT) are each associated with an increased risk for incident vascular disease, vascular disease mortality, and all-cause mortality. We conducted this study to determine if IGT and DGT are sufficiently common among patients with TIA and ischemic stroke to warrant therapeutic trials of antihyperglycemic agents.
  
  
  METHODS
  Men and women older than 45 years were recruited from 3 hospitals in south central Connecticut. Eligibility criteria included a recent TIA or nondisabling ischemic stroke, no history of physician-diagnosed diabetes mellitus, and a fasting plasma glucose level less than 126 mg/dL (<7.0 mmol / L). After an overnight fast, subjects were admitted to a clinical research center for a standard 75-g oral glucose tolerance test. Impaired glucose tolerance was defined by a 2-hour plasma glucose value of 140 to 199 mg/dL (7.8-11.0 mmol / L) and DGT by a value of 200 mg/dL or greater (> or =11.1 mmol/L).
  
  
  RESULTS
  Between June 2000 and August 2003, we enrolled 98 eligible patients. The average time from TIA or stroke to measurement of glucose tolerance was 105 days (range, 24-180 days) and the median age was 71 years. Twenty-seven subjects (28%) had IGT and 24 (24%) had diabetes. In a forward stepwise logistic regression model, only a fasting plasma glucose level of 110 mg/dL or greater (> or =6.1 mmol / L) and lower waist circumference were associated with an increased risk for IGT or DGT.
  
  
  CONCLUSIONS
  Impaired glucose tolerance and DGT are present in most persons with a recent TIA or ischemic stroke who have no history of diabetes and a fasting plasma glucose level less than 126 mg/dL (<7.0 mmol / L). Our findings bring new urgency to the initiation of research to examine the effectiveness of antihyperglycemic therapies among patients with cerebrovascular disease and abnormal glucose tolerance.
authors.affiliation: Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520-8025, USA. walter.kernan@yale.edu
authors.forename: Walter N
authors.initials: WN
authors.lastname: Kernan
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Viscoli
authors.forename: Silvio E
authors.initials: SE
authors.lastname: Inzucchi
authors.forename: Lawrence M
authors.initials: LM
authors.lastname: Brass
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Bravata
authors.forename: Gerald I
authors.initials: GI
authors.lastname: Shulman
authors.forename: James C
authors.initials: JC
authors.lastname: McVeety
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000032:analysis*; D015331:Cohort Studies; D005260:Female; D018149:Glucose Intolerance / Q000175:diagnosis / Q000453:epidemiology*; D005951:Glucose Tolerance Test; D006801:Humans; D002546:Ischemic Attack, Transient / Q000175:diagnosis* / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D020521:Stroke / Q000175:diagnosis* / Q000453:epidemiology
chemical_list: D001786:Blood Glucose